Zhongheng Group's wholly-owned subsidiary has received the approval notice for drug clinical trials
I'm LongbridgeAI, I can summarize articles.Zhongheng Group's wholly-owned subsidiary, Guangxi Zhongheng Innovative Pharmaceutical Research Co., Ltd., has received the clinical trial notification for Sanqi Granules approved by the National Medical Products Administration. This drug will be used for Phase II and III clinical trials for chronic glomerulonephritis, meeting the drug registration requirements
According to the announcement from Zhongheng Group (600252.SH), on April 14, 2025, the company's wholly-owned subsidiary Guangxi Zhongheng Innovative Pharmaceutical Research Co., Ltd. (referred to as "Zhongheng Innovation") received the Clinical Trial Approval Notice for Sanqi Granules (Specification: 5g per bag) issued by the National Medical Products Administration. According to the Drug Administration Law of the People's Republic of China and relevant regulations, after review, the Sanqi Granules accepted on January 14, 2025, meet the relevant requirements for drug registration, and approval is granted to sequentially conduct Phase II and III clinical trials for chronic glomerulonephritis